Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis

Author Year Region Follow-up (month) Age (year) No. (M/F) Sample size Outcome Cut-off value NOS score
Porrata et al. [28] 2010 USA 59.1 (13.9–107.8) 64 (20–92) 146/109 255 OS, PFS 3.5 8
Ho et al. [11] 2015 China 53.28 61.0 (16–88) 80/68 148 OS, PFS 2.11 7
Keam et al. [23] 2015 Korea 59.0 (2.5–118.5) 61 (16–87) 226/221 447 OS, PFS 3 8
Melchardt et al. [9] 2015 Austria 53 65.3 (20–92) 270/245 515 OS 5.54 8
Ming et al. [29] 2015 China NR 55 (20–85) 24/27 51 OS 2.32 6
Hong et al. [22] 2016 Korea 48.9 (46.5–51.3) 56 (16–86) 177/136 313 PFS 2.42 8
Ni et al. [27] 2016 China NR 54 (14–75) 36/23 59 OS, PFS 2.915 6
Periša et al. [25] 2016 Croatia 27 (1–105) 63 (22–87) 51/66 117 OS, EFS 2.63 6
Wang et al. [26] 2016 China 29 (2–122) NR 90/66 156 OS, PFS 3.0 6
Park et al. [24] 2016 Korea NR 60 (32–81) 53/46 99 OS, PFS 3.5 6
Wang et al. [8] 2017 China NR 54 (18–86) 202/153 355 OS, PFS 2.81 7
  1. NR not reported, OS overall survival, PFS progression free survival, EFS event free survival, NOS Newcastle–Ottawa Quality Assessment Scale